David Roman
Stock Analyst at Goldman Sachs
(2.11)
# 3,133
Out of 5,182 analysts
80
Total ratings
43.48%
Success rate
-3.91%
Average return
Main Sectors:
Stocks Rated by David Roman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BSX Boston Scientific | Maintains: Buy | $87 → $84 | $58.45 | +43.71% | 3 | Apr 23, 2026 | |
| BDX Becton, Dickinson and Company | Reinstates: Neutral | $167 | $149.52 | +11.69% | 2 | Apr 10, 2026 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $28 → $25 | $18.63 | +34.19% | 3 | Apr 9, 2026 | |
| SYK Stryker | Maintains: Neutral | $403 → $357 | $321.43 | +11.07% | 3 | Apr 9, 2026 | |
| OMDA Omada Health | Maintains: Buy | $26 → $23 | $14.59 | +57.64% | 2 | Apr 9, 2026 | |
| KMTS Kestra Medical Technologies | Maintains: Neutral | $22 → $17 | $21.66 | -21.51% | 4 | Apr 9, 2026 | |
| IRTC iRhythm Holdings | Maintains: Neutral | $184 → $147 | $125.41 | +17.22% | 5 | Apr 9, 2026 | |
| ISRG Intuitive Surgical | Maintains: Buy | $714 → $609 | $466.64 | +30.51% | 2 | Apr 9, 2026 | |
| PODD Insulet | Maintains: Buy | $326 → $277 | $182.87 | +51.47% | 3 | Apr 9, 2026 | |
| GEHC GE HealthCare Technologies | Maintains: Buy | $97 → $81 | $68.50 | +18.25% | 4 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $34 → $28 | $24.57 | +13.96% | 6 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $17 | $9.07 | +87.43% | 2 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $20 | $10.08 | +98.41% | 4 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $121 | $93.86 | +28.92% | 3 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $21 → $17 | $17.94 | -5.24% | 5 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $95 | $82.28 | +15.46% | 5 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $49 | $44.24 | +10.76% | 1 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $89 | $81.18 | +9.63% | 4 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $64 → $71 | $63.09 | +12.54% | 2 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $81 → $111 | $81.90 | +35.53% | 2 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $15.72 | +1.78% | 1 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $103 | $119.63 | -13.90% | 1 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $12.80 | +56.25% | 1 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $120 → $104 | $82.80 | +25.60% | 2 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $10 | $6.00 | +66.67% | 4 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $63 → $71 | $67.51 | +5.17% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $55 | $61.29 | -10.26% | 2 | Mar 3, 2025 |
Boston Scientific
Apr 23, 2026
Maintains: Buy
Price Target: $87 → $84
Current: $58.45
Upside: +43.71%
Becton, Dickinson and Company
Apr 10, 2026
Reinstates: Neutral
Price Target: $167
Current: $149.52
Upside: +11.69%
Tandem Diabetes Care
Apr 9, 2026
Maintains: Neutral
Price Target: $28 → $25
Current: $18.63
Upside: +34.19%
Stryker
Apr 9, 2026
Maintains: Neutral
Price Target: $403 → $357
Current: $321.43
Upside: +11.07%
Omada Health
Apr 9, 2026
Maintains: Buy
Price Target: $26 → $23
Current: $14.59
Upside: +57.64%
Kestra Medical Technologies
Apr 9, 2026
Maintains: Neutral
Price Target: $22 → $17
Current: $21.66
Upside: -21.51%
iRhythm Holdings
Apr 9, 2026
Maintains: Neutral
Price Target: $184 → $147
Current: $125.41
Upside: +17.22%
Intuitive Surgical
Apr 9, 2026
Maintains: Buy
Price Target: $714 → $609
Current: $466.64
Upside: +30.51%
Insulet
Apr 9, 2026
Maintains: Buy
Price Target: $326 → $277
Current: $182.87
Upside: +51.47%
GE HealthCare Technologies
Apr 9, 2026
Maintains: Buy
Price Target: $97 → $81
Current: $68.50
Upside: +18.25%
Apr 9, 2026
Maintains: Neutral
Price Target: $34 → $28
Current: $24.57
Upside: +13.96%
Apr 9, 2026
Maintains: Buy
Price Target: $19 → $17
Current: $9.07
Upside: +87.43%
Apr 9, 2026
Maintains: Buy
Price Target: $23 → $20
Current: $10.08
Upside: +98.41%
Apr 9, 2026
Maintains: Buy
Price Target: $140 → $121
Current: $93.86
Upside: +28.92%
Feb 17, 2026
Maintains: Neutral
Price Target: $21 → $17
Current: $17.94
Upside: -5.24%
Feb 11, 2026
Maintains: Buy
Price Target: $108 → $95
Current: $82.28
Upside: +15.46%
Jan 12, 2026
Initiates: Buy
Price Target: $49
Current: $44.24
Upside: +10.76%
Jan 9, 2026
Downgrades: Sell
Price Target: $89
Current: $81.18
Upside: +9.63%
Dec 8, 2025
Maintains: Sell
Price Target: $64 → $71
Current: $63.09
Upside: +12.54%
Nov 19, 2025
Upgrades: Neutral
Price Target: $81 → $111
Current: $81.90
Upside: +35.53%
Oct 1, 2025
Initiates: Neutral
Price Target: $16
Current: $15.72
Upside: +1.78%
Oct 1, 2025
Initiates: Buy
Price Target: $103
Current: $119.63
Upside: -13.90%
Aug 25, 2025
Initiates: Buy
Price Target: $20
Current: $12.80
Upside: +56.25%
May 6, 2025
Maintains: Neutral
Price Target: $120 → $104
Current: $82.80
Upside: +25.60%
May 1, 2025
Maintains: Buy
Price Target: $13 → $10
Current: $6.00
Upside: +66.67%
Mar 3, 2025
Maintains: Sell
Price Target: $63 → $71
Current: $67.51
Upside: +5.17%
Mar 3, 2025
Maintains: Buy
Price Target: $64 → $55
Current: $61.29
Upside: -10.26%